ClinicalTrials.gg
CompletedNCT00278915FMASUpdated Mar 5, 2024Results posted

Faslodex in McCune-Albright Syndrome

A Phase 2 interventional study of Fulvestrant in Puberty, Precocious and McCune-Albright Syndrome, sponsored by AstraZeneca. Completed at 16 sites in 6 countries. Open to female participants aged 1 Year to 10 Years. Per ClinicalTrials.gov, last updated 2024-03-05.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
1 Year to 10 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Puberty, Precocious with a site in United States — 4 open to participants now, 5 under way, 1 of them phase 3. Puberty, Precocious · United States.

Enrollment
11th of 15
30 · median 55
Started
2006
with 2 others
Phase 2
5 of 21
1 open now
Registered
7th of 21
by date
Lead sponsor
2 of 21
AstraZeneca

Among the 21 studies in Puberty, Precocious with a site in United States, this one is the 11th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2006, is one of 5 in phase 2, and was the 7th registered.

Puberty, Precocious

75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.

Browse Puberty, Precocious studies →

Open to participants now

4 of the 21 studies in Puberty, Precocious with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 1 Year to 10 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Puberty, Precocious with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, effectiveness and pharmacokinetics of a study drug called Faslodex (fulvestrant) in the treatment of progressive precocious puberty (PPP) (early puberty) in girls with McCune-Albright syndrome (MAS)

03

Conditions studied

  • Puberty, Precocious
  • McCune-Albright Syndrome

Keywords

  • Progressive Precocious Puberty
  • PPP
  • McCune-Albright Syndrome
  • MAS
04

Who can participate

Ages eligible
1 Year to 10 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females less than or equal to 10 years of age (prior to 11th birthday)
  • Diagnosis of MAS
  • PPP associated with MAS

Exclusion criteria

Exclusion Criteria:

  • Received any prior treatment for PPP associated with MAS with fulvestrant
  • Abnormal count or liver function tests
  • Bleeding disorders
  • Long term anticoagulation therapy
  • Known to any component of the study drug
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Fulvestrant

    Participants will receive intramuscular injection of fulvestrant 2 mg/kg or 4 mg/kg (First 10 participants will be dosed at 2 mg/kg then increased to 4 mg/kg. All subsequent participants will be dosed at 4 mg/kg) into the buttock or thigh monthly for 12 months or until the participant demonstrates lack of efficacy based upon one or more of the primary endpoints or experiences a serious drug-related toxicity requiring treatment discontinuation.

    Drug: Fulvestrant

Interventions

  • Participants will receive intramuscular injection of fulvestrant as stated in arm description.

    Also known as: Faslodex, ZD9238

06

What researchers measure

Primary outcomes

  1. Change in Frequency of Annualized Days of Vaginal Bleeding on Treatment Compared to Baseline

    Vaginal bleeding days are defined as the number of days in which vaginal bleeding, (including spotting) occurred. In order to annualize, a 12-month period is defined as 360 days and a 6-month period is defined as 180 days. Frequency of annualized vaginal bleeding days = \[(number of vaginal bleeding days)/(total number of days of the time interval under consideration)\] multiplied by 360. Change in frequency is equal to the on-treatment frequency minus the baseline frequency. Diary cards will capture days of vaginal bleeding during the 12-month treatment period. Change in the frequency of annualized days of vaginal bleeding during the 12-month treatment period compared to the 6-month baseline period, based on a worst-case scenario calculation (ie, missing diary card days counted as bleeding days) are reported.

    Time frame: Baseline (6 month pre-treatment observation period) through Month 12 treatment period

  2. Percentage of Participants With Baseline Vaginal Bleeding Who Experienced ≥ 50% Reduction in the Number of Vaginal Bleeding Days on Treatment Compared to Baseline

    The percentage change in frequency is defined as 100% times the difference (the on-treatment period frequency minus the baseline period frequency), divided by the baseline period frequency. The percentage of participants with baseline vaginal bleeding days who experienced ≥ 50% reduction in the number of vaginal bleeding days during the 12 month treatment period compared to the 6 month baseline period based on a worst-case approach (ie, missing diary card days counted as bleeding days) are reported.

    Time frame: Baseline (6 month pre-treatment observation period) through Month 12 treatment period

  3. Percentage of Participants With Baseline Vaginal Bleeding Who Experienced Cessation of Vaginal Bleeding Over a 6-month Treatment Period

    Percentage of participants with baseline vaginal bleeding who experienced cessation of vaginal bleeding days over a 6-month treatment period based on a worst-case approach (ie, missing diary card days counted as bleeding days) are reported.

    Time frame: Baseline (6-month pre-treatment observation period) through Month 12 treatment period

  4. Percentage of Participants With Baseline Vaginal Bleeding Who Experienced Cessation of Vaginal Bleeding Over the Whole 12-month Treatment Period

    Percentage of participants with baseline vaginal bleeding who experienced cessation of vaginal bleeding days over a 12-month treatment period based on a worst-case approach (ie, missing diary card days counted as bleeding days) are reported.

    Time frame: Baseline (6 month pre-treatment observation period) through Month 12 treatment period

  5. Change in Rate of Bone Age (BA) Advancement Over First 6-month Treatment Period Compared to Baseline

    Change in rate of BA advancement over first 6-month treatment period compared to baseline (6-month pre-treatment observation period) is reported. Increase in BA is defined as BA (expressed as fractional years) at end of time period minus BA at beginning of time period (unit: years). Rate of increase in BA for a particular time interval is increase in BA during this time interval adjusted (ie, normalized) for the length of this time interval. Rate of BA advancement is change in BA (years) divided by change in chronological age (CA) (years). Change in rate of increase in BA from baseline period to on-treatment period is defined as increase in BA divided by change in CA (in fractional years) between BA radiograph dates. It is calculated as \[(BA6 - BA0)/(CA6 - CA0)\] - \[(BA0 - BA\*)/(CA0 - CA\*)\], where 6, 0, \* stand for first Month 6 Visit, Month 0 Visit, and the 6-month retrospective visit, respectively.

    Time frame: Baseline (6-month pre-treatment observation period) through Month 6 of treatment period

  6. Change in Rate of BA Advancement Over Second 6-month Treatment Period Compared to Baseline

    Change in rate of BA advancement over second 6-month treatment period compared to baseline (6-month pre-treatment observation period) is reported. Increase in BA is defined as BA (expressed as fractional years) at end of time period minus BA at beginning of time period (unit: years). Rate of increase in BA for a particular time interval is increase in BA during this time interval adjusted (ie, normalized) for the length of this time interval. Rate of BA advancement is change in BA (years) divided by change in CA (years). Change in rate of increase in BA from baseline period to on-treatment period is defined as increase in BA divided by change in CA (in fractional years) between the BA radiograph dates. It is calculated as \[(BA6 - BA0)/(CA6 - CA0)\] - \[(BA0 - BA\*)/(CA0 - CA\*)\], where 6, 0, \* stand for second Month 6 Visit, Month 0 Visit, and the 6-month retrospective visit, respectively.

    Time frame: Baseline (6-month pre-treatment observation period) through second Month 6 of treatment period

  7. Change in Rate of BA Advancement Over the Whole 12-month Treatment Period Compared to Baseline

    Change in rate of BA advancement over whole 12-month treatment period compared to baseline (6-month pre-treatment observation period) is reported. Increase in BA is defined as BA (expressed as fractional years) at end of time period minus BA at beginning of time period (unit: years). Rate of increase in BA for a particular time interval is increase in BA during this time interval adjusted (ie, normalized) for the length of this time interval. Rate of BA advancement is change in BA (years) divided by change in CA (years). Change in rate of increase in BA from baseline period to on-treatment period is defined as increase in BA divided by change in CA (in fractional years) between the BA radiograph dates. It is calculated as \[(BA12 - BA0) / (CA12 - CA0)\] - \[(BA0 - BA\*) / (CA0 - CA\*)\], where 12, 0, \* stand for Month 12 Visit, Month 0 Visit, and the 6-month retrospective visit, respectively.

    Time frame: Baseline (6-month pre-treatment observation period) through Month 12 of treatment period

  8. Change in Growth Velocity (Annualized Growth Velocity in cm/Year) Over First 6-month Treatment Period Compared to Baseline

    Change in growth velocity (annualized growth velocity in cm/year) from the baseline (pre-treatment period) to first 6-month treatment period is reported. Growth velocity for a particular time period was calculated as the increase in height over that time period divided by the length of that time period (expressed in cm/year). Baseline growth velocity was calculated from 6-month observational/retrospective period of the study. Change in growth velocity was calculated as growth velocity on treatment minus change in growth velocity during baseline.

    Time frame: Baseline (6 month pre-treatment observation period) through first 6-month of treatment period

  9. Change in Growth Velocity (Annualized Growth Velocity in cm/Year) Over Second 6-month Treatment Period Compared to Baseline

    Change in growth velocity (annualized growth velocity in cm/year) from the baseline (pre-treatment period) to second 6-month treatment period is reported. Growth velocity for a particular time period was calculated as the increase in height over that time period divided by the length of that time period (expressed in cm/year). Baseline growth velocity was calculated from 6-month observational/retrospective period of the study. Change in growth velocity was calculated as growth velocity on treatment minus change in growth velocity during baseline.

    Time frame: Baseline (6 month pre-treatment observation period) through second 6-month treatment period (ie, through 12-month treatment period)

  10. Change in Growth Velocity (Annualized Growth Velocity in cm/Year) Over Whole 12-month Treatment Period Compared to Baseline

    Change in growth velocity (annualized growth velocity in cm/year) from the baseline (pre-treatment period) to the 12-month treatment period is reported. Growth velocity for a particular time period was calculated as the increase in height over that time period divided by the length of that time period (expressed in cm/year). Baseline growth velocity was calculated from 6-month observational/retrospective period of the study. Change in growth velocity was calculated as growth velocity on treatment minus change in growth velocity during baseline.

    Time frame: Baseline (6 month pre-treatment observation period) through Month 12 of treatment period

  11. Change in Growth Velocity (Z-score) Over the First 6-month Treatment Period Compared to Baseline

    Change in growth velocity (Z-score) from baseline period to the first 6 months of treatment period is reported. The Z-score (also known as Standard Deviation Score \[SDS\]) is defined as \[(growth velocity from the previous visit to the current visit minus mean growth velocity) divided by standard deviation (SD)\], where the mean and SD are the age- and gender-specific statistics for growth velocity from the National Center for Health Statistics, Fels study and age is the age at the current visit. Baseline growth velocity was calculated from 6-month observational/retrospective period of the study. Z-score of 0 represents the population mean for growth velocity. For McCune-Albright Syndrome, Z-score below mean is a better outcome.

    Time frame: Baseline (6 month pre-treatment observation period) through first 6-month treatment period

  12. Change in Growth Velocity (Z-score) Over the Second 6-month Treatment Period Compared to Baseline

    Change in growth velocity (Z-score) from baseline period to the second 6 months of treatment period is reported. The Z-score (also known as SDS) is defined as \[(growth velocity from the previous visit to the current visit minus mean growth velocity) divided by SD\], where the mean and SD are the age- and gender-specific statistics for growth velocity from the National Center for Health Statistics, Fels study and age is the age at the current visit. Baseline growth velocity was calculated from 6-month observational/retrospective period of the study. Z-score of 0 represents the population mean for growth velocity. For McCune-Albright Syndrome, Z-score below mean is a better outcome.

    Time frame: Baseline (6 month pre-treatment observation period) through second 6-month treatment period

  13. Change in Growth Velocity (Z-score) Over the Whole 12-month Treatment Period Compared to Baseline

    Change in growth velocity (Z-score) from baseline period to 12 months of treatment period is reported. The Z-score (also known as SDS) is defined as \[(growth velocity from the previous visit to the current visit minus mean growth velocity) divided by SD)\], where the mean and SD are the age- and gender-specific statistics for growth velocity from the National Center for Health Statistics, Fels study and age is the age at the current visit. Baseline growth velocity was calculated from 6-month observational/retrospective period of the study. Z-score of 0 represents the population mean for growth velocity. For McCune-Albright Syndrome, Z-score below mean is a better outcome.

    Time frame: Baseline (6 month pre-treatment observation period) through Month 12 of treatment period

  14. Change in Uterine Volume From Baseline to Month 6 as Assessed by Ultrasound

    Uterine volume was calculated via ultrasound using the formula: 0.5 multiplied by (longitudinal multiplied by anteroposterior multiplied by transverse), if all 3 linear dimensions were recorded. If all 3 linear dimensions were not recorded, uterine volume was not calculated. Change in uterine volume from baseline to Month 6 was calculated as Month 6 volume (by ultrasound) minus screening visit volume (by ultrasound). Baseline (screening visit) is the pre-treatment baseline visit.

    Time frame: Baseline (pre-treatment baseline visit) and Month 6 of treatment period

  15. Change in Uterine Volume From Month 6 to Month 12/Final Visit as Assessed by Ultrasound

    Uterine volume was calculated via ultrasound using the formula: 0.5 multiplied by (longitudinal multiplied by anteroposterior multiplied by transverse), if all 3 linear dimensions were recorded. If all 3 linear dimensions were not recorded, uterine volume was not calculated. Change in uterine volume from Month 6 to Month 12/final visit was calculated as Month 12/finial visit volume (by ultrasound) minus Month 6 volume (by ultrasound).

    Time frame: At Month 6 and Month 12/final visit treatment period

  16. Change in Uterine Volume From Baseline to Month 12/Final Visit as Assessed by Ultrasound

    Uterine volume was calculated via ultrasound using the formula: 0.5 multiplied by (longitudinal multiplied by anteroposterior multiplied by transverse), if all 3 linear dimensions were recorded. If all 3 linear dimensions were not recorded, uterine volume was not calculated. Change in uterine volume from baseline to Month 12/final visit was calculated as End of Study volume (by ultrasound) minus Screening Visit volume (by ultrasound). Baseline (screening visit) is the pre-treatment baseline visit.

    Time frame: Baseline (pre-treatment screening visit) and Month 12 treatment period

  17. Change in Mean Ovarian Volume From Baseline to Month 6 as Assessed by Ultrasound

    The mean ovarian volume was the average of both ovaries. Average volume was calculated as 0.5 multiplied by (volume of left ovary plus volume of right ovary) if both volumes were calculated; otherwise, average ovarian volume was considered missing. The volume of each ovary was calculated via ultrasound using the formula: 0.5 multiplied by longitudinal dimension multiplied by anterior-posterior dimension multiplied by transverse dimension. Change in mean ovarian volume from baseline to Month 6 was calculated as Month 6 mean volume minus Screening Visit mean volume. Baseline (screening visit) is the pre-treatment baseline visit.

    Time frame: Baseline (pre-treatment screening visit) and Month 6 of treatment period

  18. Change Mean in Ovarian Volume From Month 6 to Month 12/Final Visit as Assessed by Ultrasound

    The mean ovarian volume was the average of both ovaries. Average volume was calculated as 0.5 multiplied by (volume of left ovary plus volume of right ovary) if both volumes were calculated; otherwise, average ovarian volume was considered missing. The volume of each ovary was calculated via ultrasound using the formula: 0.5 multiplied by longitudinal dimension multiplied by anterior-posterior dimension multiplied by transverse dimension. Change in mean ovarian volume from Month 6 to Month 12/final visit was calculated as Month 12/final visit mean volume minus Month 6 mean volume.

    Time frame: At Month 6 and Month 12/final visit treatment period

  19. Change in Mean Ovarian Volume From Baseline to Month 12/Final Visit as Assessed by Ultrasound

    The mean ovarian volume was the average of both ovaries. Average ovarian volume was calculated as 0.5 multiplied by (volume of left ovary plus volume of right ovary) if both volumes were calculated; otherwise, average ovarian volume was considered missing. The volume of each ovary was calculated via ultrasound using the formula: 0.5 multiplied by longitudinal dimension multiplied by anterior-posterior dimension multiplied by transverse dimension. Change in mean ovarian volume from baseline to the end of the study was calculated as End of Study mean volume minus Screening Visit mean volume. Baseline (screening visit) is the pre-treatment baseline visit.

    Time frame: Baseline (pre-treatment baseline visit) and Month 12/final visit treatment period

  20. Mean Clearance of Fulvestrant

    Mean clearance of fulvestrant is reported.

    Time frame: Post-dose: Weeks 1, 2, 3, and pre-dose: Week 4 of Month 1 for first 6 participants, then pre-dose steady state samples on 2 occasions between Months 6 and 12 with at least 1 month in between wherein first sample drawn at least 30 days following sixth dose

  21. Mean Volume of Distribution (V1/F) of Fulvestrant

    Total apparent volume of distribution (Vss/F) is the total apparent volume in the body into which Fulvestrant distributes at equilibrium. Vss/F = V1/F + V2/F. V1/F is the volume of the first compartment and V2/F is the volume of the second compartment. V1/F of fulvestrant is reported. The measure of variability presented is the inter-individual error.

    Time frame: Post-dose: Weeks 1, 2, 3, and pre-dose: Week 4 of Month 1 for first 6 participants, then pre-dose steady state samples on 2 occasions between Months 6 and 12 with at least 1 month in between wherein first sample drawn at least 30 days following sixth dose

  22. Mean Volume of Distribution (V2/F) of Fulvestrant

    Total apparent volume of distribution (Vss/F) is the total apparent volume in the body into which Fulvestrant distributes at equilibrium. Vss/F = V1/F + V2/F. V1/F is the volume of the first compartment and V2/F is the volume of the second compartment. V2/F of fulvestrant is reported. The measure of variability presented is the inter-individual error.

    Time frame: Post-dose: Weeks 1, 2, 3, and pre-dose: Week 4 of Month 1 for first 6 participants, then pre-dose steady state samples on 2 occasions between Months 6 and 12 with at least 1 month in between wherein first sample drawn at least 30 days following sixth dose

  23. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

    Time frame: Day 1 through 68.7 weeks (maximum observed duration)

  24. Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs

    Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported. Clinical laboratory parameter analysis included hematology and clinical chemistry.

    Time frame: Day 1 through 68.7 weeks (maximum observed duration)

  25. Number of Participants With Compliance to Study Treatment

    Number of participants with compliance to study treatment are reported. Treatment compliance was ensured at each treatment visit whether each participant received all protocol-defined injections up until the point they either withdrew from the study or completed the main study period. Compliance with study treatment for each participant for the 12-month treatment period was calculated as total number of injections divided by number of visits between first injection (Month 0) and last injection (at Month 11).

    Time frame: Day 1 through Month 12 of treatment period

  26. Number of Participants With Withdrawals From Study Treatment Due to TEAE

    Number of participants with withdrawals from study treatment due to TEAE are reported.

    Time frame: Day 1 through 68.7 weeks (maximum observed duration)

  27. Hormone Assay: Serum Oestradiol Level

    Serum oestradiol level at Month 12 (final visit) is reported.

    Time frame: Month 12 (final visit) of treatment period

  28. Hormone Assay: Serum Luteinizing Hormone (LH) Level

    Serum LH level collected at Month 12 (final visit) is reported.

    Time frame: Month 12 (final visit) of treatment period

  29. Hormone Assay: Serum Follicle-stimulating Hormone (FSH) Level

    Serum FSH level collected at Month 12 (final visit) is reported.

    Time frame: Month 12 (final visit) of treatment period

  30. Hormone Assay: Serum Testosterone Level

    Serum testosterone level at Month 12 (final visit) is reported.

    Time frame: Month 12 (final visit) of treatment period

Secondary outcomes

  1. Change in Tanner Stage of Breast From Baseline to Month 12/Final Visit

    Change in Tanner stage (measure of pubertal progression) of breast from baseline to Month 12/last visit is reported. Tanner stage (breast) is a score of range 1-5 where 1 = no development and 5 = adult breast.

    Time frame: From Baseline (Month 0) through Month 12 treatment period

  2. Change in Tanner Stage of Pubic Hair From Baseline to Month 12/Final Visit

    Change in Tanner stage (measure of pubertal progression) of pubic hair from baseline to Month 12/final visit is reported. Tanner stage (pubic hair) is a score of range 1-5 where 1 = no development and 5 = adult pubic hair.

    Time frame: From Baseline (Month 0) through Month 12 treatment period

  3. Change in Predicted Adult Height (PAH) From Baseline to Month 12/Final Visit

    Change in PAH for children over age 6 is reported. Bone age radiographs were collected retrospectively. PAH equals the current height divided by a factor (the fraction of final adult height) based on current bone age (central read) and current bone age relative to chronological age, classified as retarded, average or advanced. Retarded is defined as current bone age (years) \< chronological age (years) minus 1; advanced is defined as current bone age (years) \> chronological age (years) plus 1; otherwise, bone age is classified as average. The PAH was summarized using the Bayley and Pinneau method.

    Time frame: From Baseline (screening visit) through Month 12 treatment period

  4. Percentage of Participants With McCune-Albright Syndrome (MAS) Associated G Protein α-subunit (Gsα) Mutation

    The MAS is caused by an activating mutation in the gene coding for the stimulatory subunit of the G protein, Gsα. The altered Gsα causes autonomous activation of G-protein stimulated cyclic adenosine monophosphate (cAMP) formation, which in the gonads, results in episodic uncontrolled sex steroid production and subsequent pubertal development. For participants who provided separate specific informed consent, the percentage of participants with a Gsα mutation at screening was assessed by molecular analysis of peripheral blood.

    Time frame: Baseline (screening)

07

Results

Posted Jul 19, 2011
Limitations and caveats
Data for exploration on body weight and race effect on fulvestrant PK is not available due to small sample size. Data for number and size of ovarian cysts at different time-point were too sparse to produce a meaningful summary, hence not reported.

Participant flow

The study was conducted at study sites located in France, Germany, Italy, Russian Federation, United Kingdom, and the United States of America.

Participant flow — Overall Study
MilestoneFulvestrant
Started30
Completed29
Not completed1
Withdrew: Disease progression1

Outcome measures

PrimaryChange in Frequency of Annualized Days of Vaginal Bleeding on Treatment Compared to Baseline

Vaginal bleeding days are defined as the number of days in which vaginal bleeding, (including spotting) occurred. In order to annualize, a 12-month period is defined as 360 days and a 6-month period is defined as 180 days. Frequency of annualized vaginal bleeding days = \[(number of vaginal bleeding days)/(total number of days of the time interval under consideration)\] multiplied by 360. Change in frequency is equal to the on-treatment frequency minus the baseline frequency. Diary cards will capture days of vaginal bleeding during the 12-month treatment period. Change in the frequency of annualized days of vaginal bleeding during the 12-month treatment period compared to the 6-month baseline period, based on a worst-case scenario calculation (ie, missing diary card days counted as bleeding days) are reported.

Time frame:
Baseline (6 month pre-treatment observation period) through Month 12 treatment period
Reported as:
Median · Days per year
Change in Frequency of Annualized Days of Vaginal Bleeding on Treatment Compared to Baseline
Days per yearFulvestrant
Change in Frequency of Annualized Days of Vaginal Bleeding on Treatment Compared to Baseline-3.6 (-42 to 185)
PrimaryPercentage of Participants With Baseline Vaginal Bleeding Who Experienced ≥ 50% Reduction in the Number of Vaginal Bleeding Days on Treatment Compared to Baseline

The percentage change in frequency is defined as 100% times the difference (the on-treatment period frequency minus the baseline period frequency), divided by the baseline period frequency. The percentage of participants with baseline vaginal bleeding days who experienced ≥ 50% reduction in the number of vaginal bleeding days during the 12 month treatment period compared to the 6 month baseline period based on a worst-case approach (ie, missing diary card days counted as bleeding days) are reported.

Time frame:
Baseline (6 month pre-treatment observation period) through Month 12 treatment period
Reported as:
Number · Percentage of Participants
Percentage of Participants With Baseline Vaginal Bleeding Who Experienced ≥ 50% Reduction in the Number of Vaginal Bleeding Days on Treatment Compared to Baseline
Percentage of ParticipantsFulvestrant
Percentage of Participants With Baseline Vaginal Bleeding Who Experienced ≥ 50% Reduction in the Number of Vaginal Bleeding Days on Treatment Compared to Baseline73.9 (51.6 to 89.8)
PrimaryPercentage of Participants With Baseline Vaginal Bleeding Who Experienced Cessation of Vaginal Bleeding Over a 6-month Treatment Period

Percentage of participants with baseline vaginal bleeding who experienced cessation of vaginal bleeding days over a 6-month treatment period based on a worst-case approach (ie, missing diary card days counted as bleeding days) are reported.

Time frame:
Baseline (6-month pre-treatment observation period) through Month 12 treatment period
Reported as:
Number · Percentage of Participants
Percentage of Participants With Baseline Vaginal Bleeding Who Experienced Cessation of Vaginal Bleeding Over a 6-month Treatment Period
Percentage of ParticipantsFulvestrant
Percentage of Participants With Baseline Vaginal Bleeding Who Experienced Cessation of Vaginal Bleeding Over a 6-month Treatment Period78.3 (56.3 to 92.5)
PrimaryPercentage of Participants With Baseline Vaginal Bleeding Who Experienced Cessation of Vaginal Bleeding Over the Whole 12-month Treatment Period

Percentage of participants with baseline vaginal bleeding who experienced cessation of vaginal bleeding days over a 12-month treatment period based on a worst-case approach (ie, missing diary card days counted as bleeding days) are reported.

Time frame:
Baseline (6 month pre-treatment observation period) through Month 12 treatment period
Reported as:
Number · Percentage of Participants
Percentage of Participants With Baseline Vaginal Bleeding Who Experienced Cessation of Vaginal Bleeding Over the Whole 12-month Treatment Period
Percentage of ParticipantsFulvestrant
Percentage of Participants With Baseline Vaginal Bleeding Who Experienced Cessation of Vaginal Bleeding Over the Whole 12-month Treatment Period34.8 (16.4 to 57.3)
PrimaryChange in Rate of Bone Age (BA) Advancement Over First 6-month Treatment Period Compared to Baseline

Change in rate of BA advancement over first 6-month treatment period compared to baseline (6-month pre-treatment observation period) is reported. Increase in BA is defined as BA (expressed as fractional years) at end of time period minus BA at beginning of time period (unit: years). Rate of increase in BA for a particular time interval is increase in BA during this time interval adjusted (ie, normalized) for the length of this time interval. Rate of BA advancement is change in BA (years) divided by change in chronological age (CA) (years). Change in rate of increase in BA from baseline period to on-treatment period is defined as increase in BA divided by change in CA (in fractional years) between BA radiograph dates. It is calculated as \[(BA6 - BA0)/(CA6 - CA0)\] - \[(BA0 - BA\*)/(CA0 - CA\*)\], where 6, 0, \* stand for first Month 6 Visit, Month 0 Visit, and the 6-month retrospective visit, respectively.

Time frame:
Baseline (6-month pre-treatment observation period) through Month 6 of treatment period
Reported as:
Mean · Ratio
Change in Rate of Bone Age (BA) Advancement Over First 6-month Treatment Period Compared to Baseline
RatioFulvestrant
Change in Rate of Bone Age (BA) Advancement Over First 6-month Treatment Period Compared to Baseline-0.83 ± 1.507
PrimaryChange in Rate of BA Advancement Over Second 6-month Treatment Period Compared to Baseline

Change in rate of BA advancement over second 6-month treatment period compared to baseline (6-month pre-treatment observation period) is reported. Increase in BA is defined as BA (expressed as fractional years) at end of time period minus BA at beginning of time period (unit: years). Rate of increase in BA for a particular time interval is increase in BA during this time interval adjusted (ie, normalized) for the length of this time interval. Rate of BA advancement is change in BA (years) divided by change in CA (years). Change in rate of increase in BA from baseline period to on-treatment period is defined as increase in BA divided by change in CA (in fractional years) between the BA radiograph dates. It is calculated as \[(BA6 - BA0)/(CA6 - CA0)\] - \[(BA0 - BA\*)/(CA0 - CA\*)\], where 6, 0, \* stand for second Month 6 Visit, Month 0 Visit, and the 6-month retrospective visit, respectively.

Time frame:
Baseline (6-month pre-treatment observation period) through second Month 6 of treatment period
Reported as:
Mean · Ratio
Change in Rate of BA Advancement Over Second 6-month Treatment Period Compared to Baseline
RatioFulvestrant
Change in Rate of BA Advancement Over Second 6-month Treatment Period Compared to Baseline-1.10 ± 1.383
PrimaryChange in Rate of BA Advancement Over the Whole 12-month Treatment Period Compared to Baseline

Change in rate of BA advancement over whole 12-month treatment period compared to baseline (6-month pre-treatment observation period) is reported. Increase in BA is defined as BA (expressed as fractional years) at end of time period minus BA at beginning of time period (unit: years). Rate of increase in BA for a particular time interval is increase in BA during this time interval adjusted (ie, normalized) for the length of this time interval. Rate of BA advancement is change in BA (years) divided by change in CA (years). Change in rate of increase in BA from baseline period to on-treatment period is defined as increase in BA divided by change in CA (in fractional years) between the BA radiograph dates. It is calculated as \[(BA12 - BA0) / (CA12 - CA0)\] - \[(BA0 - BA\*) / (CA0 - CA\*)\], where 12, 0, \* stand for Month 12 Visit, Month 0 Visit, and the 6-month retrospective visit, respectively.

Time frame:
Baseline (6-month pre-treatment observation period) through Month 12 of treatment period
Reported as:
Mean · Ratio
Change in Rate of BA Advancement Over the Whole 12-month Treatment Period Compared to Baseline
RatioFulvestrant
Change in Rate of BA Advancement Over the Whole 12-month Treatment Period Compared to Baseline-0.93 ± 1.343
PrimaryChange in Growth Velocity (Annualized Growth Velocity in cm/Year) Over First 6-month Treatment Period Compared to Baseline

Change in growth velocity (annualized growth velocity in cm/year) from the baseline (pre-treatment period) to first 6-month treatment period is reported. Growth velocity for a particular time period was calculated as the increase in height over that time period divided by the length of that time period (expressed in cm/year). Baseline growth velocity was calculated from 6-month observational/retrospective period of the study. Change in growth velocity was calculated as growth velocity on treatment minus change in growth velocity during baseline.

Time frame:
Baseline (6 month pre-treatment observation period) through first 6-month of treatment period
Reported as:
Mean · cm/year
Change in Growth Velocity (Annualized Growth Velocity in cm/Year) Over First 6-month Treatment Period Compared to Baseline
cm/yearFulvestrant
Change in Growth Velocity (Annualized Growth Velocity in cm/Year) Over First 6-month Treatment Period Compared to Baseline-1.7 ± 4.35
PrimaryChange in Growth Velocity (Annualized Growth Velocity in cm/Year) Over Second 6-month Treatment Period Compared to Baseline

Change in growth velocity (annualized growth velocity in cm/year) from the baseline (pre-treatment period) to second 6-month treatment period is reported. Growth velocity for a particular time period was calculated as the increase in height over that time period divided by the length of that time period (expressed in cm/year). Baseline growth velocity was calculated from 6-month observational/retrospective period of the study. Change in growth velocity was calculated as growth velocity on treatment minus change in growth velocity during baseline.

Time frame:
Baseline (6 month pre-treatment observation period) through second 6-month treatment period (ie, through 12-month treatment period)
Reported as:
Mean · cm/year
Change in Growth Velocity (Annualized Growth Velocity in cm/Year) Over Second 6-month Treatment Period Compared to Baseline
cm/yearFulvestrant
Change in Growth Velocity (Annualized Growth Velocity in cm/Year) Over Second 6-month Treatment Period Compared to Baseline-0.8 ± 4.49
PrimaryChange in Growth Velocity (Annualized Growth Velocity in cm/Year) Over Whole 12-month Treatment Period Compared to Baseline

Change in growth velocity (annualized growth velocity in cm/year) from the baseline (pre-treatment period) to the 12-month treatment period is reported. Growth velocity for a particular time period was calculated as the increase in height over that time period divided by the length of that time period (expressed in cm/year). Baseline growth velocity was calculated from 6-month observational/retrospective period of the study. Change in growth velocity was calculated as growth velocity on treatment minus change in growth velocity during baseline.

Time frame:
Baseline (6 month pre-treatment observation period) through Month 12 of treatment period
Reported as:
Mean · cm/year
Change in Growth Velocity (Annualized Growth Velocity in cm/Year) Over Whole 12-month Treatment Period Compared to Baseline
cm/yearFulvestrant
Change in Growth Velocity (Annualized Growth Velocity in cm/Year) Over Whole 12-month Treatment Period Compared to Baseline-1.4 ± 3.69
PrimaryChange in Growth Velocity (Z-score) Over the First 6-month Treatment Period Compared to Baseline

Change in growth velocity (Z-score) from baseline period to the first 6 months of treatment period is reported. The Z-score (also known as Standard Deviation Score \[SDS\]) is defined as \[(growth velocity from the previous visit to the current visit minus mean growth velocity) divided by standard deviation (SD)\], where the mean and SD are the age- and gender-specific statistics for growth velocity from the National Center for Health Statistics, Fels study and age is the age at the current visit. Baseline growth velocity was calculated from 6-month observational/retrospective period of the study. Z-score of 0 represents the population mean for growth velocity. For McCune-Albright Syndrome, Z-score below mean is a better outcome.

Time frame:
Baseline (6 month pre-treatment observation period) through first 6-month treatment period
Reported as:
Mean · Unit on a score
Change in Growth Velocity (Z-score) Over the First 6-month Treatment Period Compared to Baseline
Unit on a scoreFulvestrant
Change in Growth Velocity (Z-score) Over the First 6-month Treatment Period Compared to Baseline-1.60 ± 4.616
PrimaryChange in Growth Velocity (Z-score) Over the Second 6-month Treatment Period Compared to Baseline

Change in growth velocity (Z-score) from baseline period to the second 6 months of treatment period is reported. The Z-score (also known as SDS) is defined as \[(growth velocity from the previous visit to the current visit minus mean growth velocity) divided by SD\], where the mean and SD are the age- and gender-specific statistics for growth velocity from the National Center for Health Statistics, Fels study and age is the age at the current visit. Baseline growth velocity was calculated from 6-month observational/retrospective period of the study. Z-score of 0 represents the population mean for growth velocity. For McCune-Albright Syndrome, Z-score below mean is a better outcome.

Time frame:
Baseline (6 month pre-treatment observation period) through second 6-month treatment period
Reported as:
Mean · Unit on a score
Change in Growth Velocity (Z-score) Over the Second 6-month Treatment Period Compared to Baseline
Unit on a scoreFulvestrant
Change in Growth Velocity (Z-score) Over the Second 6-month Treatment Period Compared to Baseline-0.64 ± 4.606
PrimaryChange in Growth Velocity (Z-score) Over the Whole 12-month Treatment Period Compared to Baseline

Change in growth velocity (Z-score) from baseline period to 12 months of treatment period is reported. The Z-score (also known as SDS) is defined as \[(growth velocity from the previous visit to the current visit minus mean growth velocity) divided by SD)\], where the mean and SD are the age- and gender-specific statistics for growth velocity from the National Center for Health Statistics, Fels study and age is the age at the current visit. Baseline growth velocity was calculated from 6-month observational/retrospective period of the study. Z-score of 0 represents the population mean for growth velocity. For McCune-Albright Syndrome, Z-score below mean is a better outcome.

Time frame:
Baseline (6 month pre-treatment observation period) through Month 12 of treatment period
Reported as:
Mean · Unit on a score
Change in Growth Velocity (Z-score) Over the Whole 12-month Treatment Period Compared to Baseline
Unit on a scoreFulvestrant
Change in Growth Velocity (Z-score) Over the Whole 12-month Treatment Period Compared to Baseline-1.14 ± 4.078
PrimaryChange in Uterine Volume From Baseline to Month 6 as Assessed by Ultrasound

Uterine volume was calculated via ultrasound using the formula: 0.5 multiplied by (longitudinal multiplied by anteroposterior multiplied by transverse), if all 3 linear dimensions were recorded. If all 3 linear dimensions were not recorded, uterine volume was not calculated. Change in uterine volume from baseline to Month 6 was calculated as Month 6 volume (by ultrasound) minus screening visit volume (by ultrasound). Baseline (screening visit) is the pre-treatment baseline visit.

Time frame:
Baseline (pre-treatment baseline visit) and Month 6 of treatment period
Reported as:
Median · Cubic centimeters
Change in Uterine Volume From Baseline to Month 6 as Assessed by Ultrasound
Cubic centimetersFulvestrant
Change in Uterine Volume From Baseline to Month 6 as Assessed by Ultrasound-1.10 (-15.10 to 6.04)
PrimaryChange in Uterine Volume From Month 6 to Month 12/Final Visit as Assessed by Ultrasound

Uterine volume was calculated via ultrasound using the formula: 0.5 multiplied by (longitudinal multiplied by anteroposterior multiplied by transverse), if all 3 linear dimensions were recorded. If all 3 linear dimensions were not recorded, uterine volume was not calculated. Change in uterine volume from Month 6 to Month 12/final visit was calculated as Month 12/finial visit volume (by ultrasound) minus Month 6 volume (by ultrasound).

Time frame:
At Month 6 and Month 12/final visit treatment period
Reported as:
Median · Cubic centimetres
Change in Uterine Volume From Month 6 to Month 12/Final Visit as Assessed by Ultrasound
Cubic centimetresFulvestrant
Change in Uterine Volume From Month 6 to Month 12/Final Visit as Assessed by Ultrasound-0.13 (-11.84 to 4.48)
PrimaryChange in Uterine Volume From Baseline to Month 12/Final Visit as Assessed by Ultrasound

Uterine volume was calculated via ultrasound using the formula: 0.5 multiplied by (longitudinal multiplied by anteroposterior multiplied by transverse), if all 3 linear dimensions were recorded. If all 3 linear dimensions were not recorded, uterine volume was not calculated. Change in uterine volume from baseline to Month 12/final visit was calculated as End of Study volume (by ultrasound) minus Screening Visit volume (by ultrasound). Baseline (screening visit) is the pre-treatment baseline visit.

Time frame:
Baseline (pre-treatment screening visit) and Month 12 treatment period
Reported as:
Median · Cubic centimeters
Change in Uterine Volume From Baseline to Month 12/Final Visit as Assessed by Ultrasound
Cubic centimetersFulvestrant
Change in Uterine Volume From Baseline to Month 12/Final Visit as Assessed by Ultrasound-2.44 (-10.20 to 6.56)
PrimaryChange in Mean Ovarian Volume From Baseline to Month 6 as Assessed by Ultrasound

The mean ovarian volume was the average of both ovaries. Average volume was calculated as 0.5 multiplied by (volume of left ovary plus volume of right ovary) if both volumes were calculated; otherwise, average ovarian volume was considered missing. The volume of each ovary was calculated via ultrasound using the formula: 0.5 multiplied by longitudinal dimension multiplied by anterior-posterior dimension multiplied by transverse dimension. Change in mean ovarian volume from baseline to Month 6 was calculated as Month 6 mean volume minus Screening Visit mean volume. Baseline (screening visit) is the pre-treatment baseline visit.

Time frame:
Baseline (pre-treatment screening visit) and Month 6 of treatment period
Reported as:
Median · Cubic centimetres
Change in Mean Ovarian Volume From Baseline to Month 6 as Assessed by Ultrasound
Cubic centimetresFulvestrant
Change in Mean Ovarian Volume From Baseline to Month 6 as Assessed by Ultrasound0.10 (-27.62 to 7.96)
PrimaryChange Mean in Ovarian Volume From Month 6 to Month 12/Final Visit as Assessed by Ultrasound

The mean ovarian volume was the average of both ovaries. Average volume was calculated as 0.5 multiplied by (volume of left ovary plus volume of right ovary) if both volumes were calculated; otherwise, average ovarian volume was considered missing. The volume of each ovary was calculated via ultrasound using the formula: 0.5 multiplied by longitudinal dimension multiplied by anterior-posterior dimension multiplied by transverse dimension. Change in mean ovarian volume from Month 6 to Month 12/final visit was calculated as Month 12/final visit mean volume minus Month 6 mean volume.

Time frame:
At Month 6 and Month 12/final visit treatment period
Reported as:
Median · Cubic centimetres
Change Mean in Ovarian Volume From Month 6 to Month 12/Final Visit as Assessed by Ultrasound
Cubic centimetresFulvestrant
Change Mean in Ovarian Volume From Month 6 to Month 12/Final Visit as Assessed by Ultrasound0.76 (-4.08 to 9.97)
PrimaryChange in Mean Ovarian Volume From Baseline to Month 12/Final Visit as Assessed by Ultrasound

The mean ovarian volume was the average of both ovaries. Average ovarian volume was calculated as 0.5 multiplied by (volume of left ovary plus volume of right ovary) if both volumes were calculated; otherwise, average ovarian volume was considered missing. The volume of each ovary was calculated via ultrasound using the formula: 0.5 multiplied by longitudinal dimension multiplied by anterior-posterior dimension multiplied by transverse dimension. Change in mean ovarian volume from baseline to the end of the study was calculated as End of Study mean volume minus Screening Visit mean volume. Baseline (screening visit) is the pre-treatment baseline visit.

Time frame:
Baseline (pre-treatment baseline visit) and Month 12/final visit treatment period
Reported as:
Median · Cubic centimetres
Change in Mean Ovarian Volume From Baseline to Month 12/Final Visit as Assessed by Ultrasound
Cubic centimetresFulvestrant
Change in Mean Ovarian Volume From Baseline to Month 12/Final Visit as Assessed by Ultrasound1.01 (-22.25 to 10.36)
PrimaryMean Clearance of Fulvestrant

Mean clearance of fulvestrant is reported.

Time frame:
Post-dose: Weeks 1, 2, 3, and pre-dose: Week 4 of Month 1 for first 6 participants, then pre-dose steady state samples on 2 occasions between Months 6 and 12 with at least 1 month in between wherein first sample drawn at least 30 days following sixth dose
Reported as:
Mean · Litres/hour
Mean Clearance of Fulvestrant
Litres/hourFulvestrant
Mean Clearance of Fulvestrant38.4 ± 11.56
PrimaryMean Volume of Distribution (V1/F) of Fulvestrant

Total apparent volume of distribution (Vss/F) is the total apparent volume in the body into which Fulvestrant distributes at equilibrium. Vss/F = V1/F + V2/F. V1/F is the volume of the first compartment and V2/F is the volume of the second compartment. V1/F of fulvestrant is reported. The measure of variability presented is the inter-individual error.

Time frame:
Post-dose: Weeks 1, 2, 3, and pre-dose: Week 4 of Month 1 for first 6 participants, then pre-dose steady state samples on 2 occasions between Months 6 and 12 with at least 1 month in between wherein first sample drawn at least 30 days following sixth dose
Reported as:
Mean · Litres
Mean Volume of Distribution (V1/F) of Fulvestrant
LitresFulvestrant
Mean Volume of Distribution (V1/F) of Fulvestrant33000 ± NA
PrimaryMean Volume of Distribution (V2/F) of Fulvestrant

Total apparent volume of distribution (Vss/F) is the total apparent volume in the body into which Fulvestrant distributes at equilibrium. Vss/F = V1/F + V2/F. V1/F is the volume of the first compartment and V2/F is the volume of the second compartment. V2/F of fulvestrant is reported. The measure of variability presented is the inter-individual error.

Time frame:
Post-dose: Weeks 1, 2, 3, and pre-dose: Week 4 of Month 1 for first 6 participants, then pre-dose steady state samples on 2 occasions between Months 6 and 12 with at least 1 month in between wherein first sample drawn at least 30 days following sixth dose
Reported as:
Mean · Litres
Mean Volume of Distribution (V2/F) of Fulvestrant
LitresFulvestrant
Mean Volume of Distribution (V2/F) of Fulvestrant32700 ± NA
PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

Time frame:
Day 1 through 68.7 weeks (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsFulvestrant
Any TEAEs27
Any TESAEs9
PrimaryNumber of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs

Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported. Clinical laboratory parameter analysis included hematology and clinical chemistry.

Time frame:
Day 1 through 68.7 weeks (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs
ParticipantsFulvestrant
Anemia1
Vitamin D Deficiency1
PrimaryNumber of Participants With Compliance to Study Treatment

Number of participants with compliance to study treatment are reported. Treatment compliance was ensured at each treatment visit whether each participant received all protocol-defined injections up until the point they either withdrew from the study or completed the main study period. Compliance with study treatment for each participant for the 12-month treatment period was calculated as total number of injections divided by number of visits between first injection (Month 0) and last injection (at Month 11).

Time frame:
Day 1 through Month 12 of treatment period
Reported as:
Count of participants · Participants
Number of Participants With Compliance to Study Treatment
ParticipantsFulvestrant
Number of Participants With Compliance to Study Treatment30
PrimaryNumber of Participants With Withdrawals From Study Treatment Due to TEAE

Number of participants with withdrawals from study treatment due to TEAE are reported.

Time frame:
Day 1 through 68.7 weeks (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Withdrawals From Study Treatment Due to TEAE
ParticipantsFulvestrant
Number of Participants With Withdrawals From Study Treatment Due to TEAE0
PrimaryHormone Assay: Serum Oestradiol Level

Serum oestradiol level at Month 12 (final visit) is reported.

Time frame:
Month 12 (final visit) of treatment period
Reported as:
Mean · pmol/L
Hormone Assay: Serum Oestradiol Level
pmol/LFulvestrant
Hormone Assay: Serum Oestradiol Level25.95 ± 30.718
PrimaryHormone Assay: Serum Luteinizing Hormone (LH) Level

Serum LH level collected at Month 12 (final visit) is reported.

Time frame:
Month 12 (final visit) of treatment period
Reported as:
Mean · IU/L
Hormone Assay: Serum Luteinizing Hormone (LH) Level
IU/LFulvestrant
Hormone Assay: Serum Luteinizing Hormone (LH) Level0.11 ± 0.042
PrimaryHormone Assay: Serum Follicle-stimulating Hormone (FSH) Level

Serum FSH level collected at Month 12 (final visit) is reported.

Time frame:
Month 12 (final visit) of treatment period
Reported as:
Mean · IU/L
Hormone Assay: Serum Follicle-stimulating Hormone (FSH) Level
IU/LFulvestrant
Hormone Assay: Serum Follicle-stimulating Hormone (FSH) Level1.13 ± 1.024
PrimaryHormone Assay: Serum Testosterone Level

Serum testosterone level at Month 12 (final visit) is reported.

Time frame:
Month 12 (final visit) of treatment period
Reported as:
Mean · nmol/L
Hormone Assay: Serum Testosterone Level
nmol/LFulvestrant
Hormone Assay: Serum Testosterone Level0.65 ± 0.273
SecondaryChange in Tanner Stage of Breast From Baseline to Month 12/Final Visit

Change in Tanner stage (measure of pubertal progression) of breast from baseline to Month 12/last visit is reported. Tanner stage (breast) is a score of range 1-5 where 1 = no development and 5 = adult breast.

Time frame:
From Baseline (Month 0) through Month 12 treatment period
Reported as:
Median · Unit on a scale
Change in Tanner Stage of Breast From Baseline to Month 12/Final Visit
Unit on a scaleFulvestrant
Change in Tanner Stage of Breast From Baseline to Month 12/Final Visit0.0 (-3 to 2)
SecondaryChange in Tanner Stage of Pubic Hair From Baseline to Month 12/Final Visit

Change in Tanner stage (measure of pubertal progression) of pubic hair from baseline to Month 12/final visit is reported. Tanner stage (pubic hair) is a score of range 1-5 where 1 = no development and 5 = adult pubic hair.

Time frame:
From Baseline (Month 0) through Month 12 treatment period
Reported as:
Median · Unit on a scale
Change in Tanner Stage of Pubic Hair From Baseline to Month 12/Final Visit
Unit on a scaleFulvestrant
Change in Tanner Stage of Pubic Hair From Baseline to Month 12/Final Visit0.0 (-2 to 1)
SecondaryChange in Predicted Adult Height (PAH) From Baseline to Month 12/Final Visit

Change in PAH for children over age 6 is reported. Bone age radiographs were collected retrospectively. PAH equals the current height divided by a factor (the fraction of final adult height) based on current bone age (central read) and current bone age relative to chronological age, classified as retarded, average or advanced. Retarded is defined as current bone age (years) \< chronological age (years) minus 1; advanced is defined as current bone age (years) \> chronological age (years) plus 1; otherwise, bone age is classified as average. The PAH was summarized using the Bayley and Pinneau method.

Time frame:
From Baseline (screening visit) through Month 12 treatment period
Reported as:
Mean · Centimeter
Change in Predicted Adult Height (PAH) From Baseline to Month 12/Final Visit
CentimeterFulvestrant
Change in Predicted Adult Height (PAH) From Baseline to Month 12/Final Visit0.5 ± 4.10
SecondaryPercentage of Participants With McCune-Albright Syndrome (MAS) Associated G Protein α-subunit (Gsα) Mutation

The MAS is caused by an activating mutation in the gene coding for the stimulatory subunit of the G protein, Gsα. The altered Gsα causes autonomous activation of G-protein stimulated cyclic adenosine monophosphate (cAMP) formation, which in the gonads, results in episodic uncontrolled sex steroid production and subsequent pubertal development. For participants who provided separate specific informed consent, the percentage of participants with a Gsα mutation at screening was assessed by molecular analysis of peripheral blood.

Time frame:
Baseline (screening)
Reported as:
Number · Percentage of participants
Percentage of Participants With McCune-Albright Syndrome (MAS) Associated G Protein α-subunit (Gsα) Mutation
Percentage of participantsFulvestrant
Percentage of Participants With McCune-Albright Syndrome (MAS) Associated G Protein α-subunit (Gsα) Mutation23.3

Adverse events

Collected over Day 1 through 68.7 weeks (maximum observed duration). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fulvestrant0/30 (0%)9/30 (30%)25/30 (83.3%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventFulvestrant
PyrexiaGeneral disorders1/30
BronchitisInfections and infestations1/30
Viral InfectionInfections and infestations1/30
Femur FractureInjury, poisoning and procedural complications1/30
DehydrationMetabolism and nutrition disorders1/30
ArthralgiaMusculoskeletal and connective tissue disorders1/30
Bone PainMusculoskeletal and connective tissue disorders1/30
Pain In ExtremityMusculoskeletal and connective tissue disorders1/30
DizzinessNervous system disorders1/30
NeuromyopathyNervous system disorders1/30
Most frequent other events
Showing 10 of 40
Most frequent other events
EventFulvestrant
PyrexiaGeneral disorders14/30
Abdominal PainGastrointestinal disorders8/30
VomitingGastrointestinal disorders8/30
HeadacheNervous system disorders8/30
CoughRespiratory, thoracic and mediastinal disorders7/30
RhinitisInfections and infestations6/30
DiarrhoeaGastrointestinal disorders5/30
Upper Respiratory Tract InfectionInfections and infestations5/30
Pain In ExtremityMusculoskeletal and connective tissue disorders5/30
Injection Site InflammationGeneral disorders4/30

Baseline characteristics

The full-analysis set (FAS) population included participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)Fulvestrant
Mean5.86 ± 1.846
Sex: Female, Male
Sex: Female, Male(Participants)Fulvestrant
Female30
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Fulvestrant
Hispanic or Latino3
Not Hispanic or Latino4
Unknown or Not Reported23
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Fulvestrant
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White26
More than one race2
Unknown or Not Reported1
08

Study locations

16 sites
  • Research Site
    Birmingham, Alabama 35233, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Lexington, Kentucky 40508, United States
  • Research Site
    Baton Rouge, Louisiana 70808, United States
  • Research Site
    Bronx, New York 10467, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Salt Lake City, Utah 84108, United States
  • Research Site
    Bordeaux, 33000, France
  • Research Site
    Bron, 69677, France
  • Research Site
    Paris Cedex 12, 75571, France
  • Research Site
    Erlangen, 91054, Germany
  • Research Site
    Osnabrück, 49082, Germany
  • Research Site
    Torino, 10126, Italy
  • Research Site
    Moscow, 117036, Russian Federation
  • Research Site
    Liverpool, L12 2AP, United Kingdom
  • Research Site
    London, WC1N 3JH, United Kingdom
09

References and documents

Publications

  • Sims EK, Garnett S, Guzman F, Paris F, Sultan C, Eugster EA; Fulvestrant McCune-Albright study group. Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome. Int J Pediatr Endocrinol. 2012 Sep 22;2012(1):26. doi: 10.1186/1687-9856-2012-26. PubMed 22999294 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2006 to primary completion in Dec 2009, 46 months.

Results were first posted in Jul 2011, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2006
First posted
Jan 19, 2006
StartActual
Jan 31, 2006
Primary completionActual
Dec 8, 2009
CompletionActual
Jul 20, 2023
Results first posted
Jul 19, 2011
Last update
Mar 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00278915
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 19, 2006
Start date
Jan 31, 2006
Primary completion
Dec 8, 2009
Completion
Jul 20, 2023
Results posted
Jul 19, 2011
Last update
Mar 5, 2024

Study contacts

AstraZeneca Faslodex Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion